Meridian Bioscience, Inc. provided consolidated revenue guidance of flat to 2% growth based on lower growth expectations in diagnostics as well as the softer-than-expected order patterns in the first quarter in its Life Science business. GAAP operating margin guidance is now approximately 19%, representing primarily the expectation for litigation expense carryover in the fiscal 2019. GAAP EPS guidance of $0.72 to $0.74.